Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Fresenius SE & KGaA
Acquired Company
mAbxience
MadridMadridBiotechnologyHealth CareBiotechnologyDescription
Fresenius has successfully acquired the remaining 45 percent of mAbxience, finalizing the deal on September 30, 2026. This transaction, valued at EUR 750 million, grants Fresenius full ownership and control of the biosimilars platform. The acquisition is expected to contribute significantly to Fresenius's core earnings. Additionally, the deal includes a contingent payment of EUR 50 million.
Fundz sees it the moment Fresenius SE & KGaA makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired mAbxience?
mAbxience was acquired by Fresenius SE & KGaA, based in Madrid. The deal was reported on October 13, 2026. Fresenius SE & Co. KGaA is a globally active healthcare group providing products and services for dialysis, the hospital, and outpatient medical care. Fresenius SE & KGaA is publicly traded (FSNUY) and operates in Biotechnology.
When did Fresenius SE & KGaA acquire mAbxience?
Fresenius SE & KGaA's acquisition of mAbxience was reported on October 13, 2026. Fresenius has successfully acquired the remaining 45 percent of mAbxience, finalizing the deal on September 30, 2026. This transaction, valued at EUR 750 million, grants Fresenius full ownership and control of the biosimilars platform. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does mAbxience do?
mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. It is privately held, operating in Biotechnology, and is based in Madrid.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.